FTC targets child supplement claims
This article was originally published in The Tan Sheet
Manufacturers of dietary supplements carrying health claims for children "can expect to see more [advertising regulatory] activity in this area" in the near future, Federal Trade Commission Associate Director for Advertising Practices Mary Engle says at American Herbal Products Association members breakfast Sept. 4. Engle attributes "grave concern" in Congress about dietary supplement advertising to children as spurring likely upcoming FTC actions. The House Energy & Commerce/Oversight & Investigations Subcommittee discussed legislation to give FDA more access to dietary supplement safety information and greater leniency to protect consumers from potentially unsafe products at July 23 meeting (1"The Tan Sheet" July 28, 2003, p. 3)...
You may also be interested in...
Reps. Henry Waxman (D-Calif.) and Susan Davis (D-Calif.) are working on legislation "that will give FDA greater access to information to understand if a [dietary supplement] product does pose a health risk and will let FDA protect consumers from unsafe products," Waxman said at a July 23 hearing of the House Energy & Commerce/Oversight & Investigations Subcommittee
Medtech Insight spoke to attorney Greg Dadika about mass tort litigation, including industry trends, how to find the right law firm, and when it’s the right time to settle a suit. See what Dadika, an attorney at the law firm Greenberg Traurig LLP, said about it here.
AstraZeneca/FibroGen’s Roxadustat Comparison To ESAs In Anemia May By Clarified At FDA Advisory Cmte.
Payers would welcome any additional clarity provided by advisory panel review, given the perception, expressed in a recent ICER report, that the evidence is insufficient to determine whether the new drug is safer or more effective than erythropoiesis-stimulating agents.